A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. Lurbinectedin is an ecteinascidin that generates DNA double-strand breaks. We hypothesized that the combination of olaparib and lurbine...

Descripción completa

Detalles Bibliográficos
Autores principales: Poveda, Andres, Oaknin, Ana, Romero, Ignacio, Guerrero-Zotano, Angel, Fariñas-Madrid, Lorena, Rodriguez-Freixinos, Victor, Mallol, Pedro, Lopez-Reig, Raquel, Lopez-Guerrero, Jose Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904806/
https://www.ncbi.nlm.nih.gov/pubmed/33627685
http://dx.doi.org/10.1038/s41598-021-82671-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904806/
https://www.ncbi.nlm.nih.gov/pubmed/33627685
http://dx.doi.org/10.1038/s41598-021-82671-w

Ejemplares similares